Serum Lipopolysaccharide (LPS) Measurement to Predict Progression of Fibrosis in Liver Transplant Recipients with Hepatitis C Virus.
To figure out the best medical follow up of patients after pancreas transplant.
The main purpose of this study is to find out whether treatment to prevent kidney rejection with belatacept in presence of Thymoglobulin induction and withdrawal of steroids will result in less delayed graft function or "sleepy kidney" after transplant than that seen in patients who get tacrolimus as their main drug to prevent rejection instead of belatacept. The investigators will also look at whether patients who get belatacept have the same, lesser or more problems that those who get tacrolimus.
A trial to determine if eculizumab is safe and could be used to prevent Delayed Graft Function after kidney transplantation.
Delayed Graft Function (DGF) is an early complication of organ transplantation, which consists of the failure of an organ to function when it is initially transplanted. Most often DGF results from ischemia/reperfusion injury (IRI), a complex pathological process that is a consequence of organ preservation.
Human donor lungs that do not meet the standard clinical criteria for donor lung utilization but fit into the study inclusion criteria will be retrieved from the donor using current donor lung retrieval techniques.
Over the last 20 years liver transplantation has become the standard of care and the only cure for end stage liver disease. Its success has led to over 4,500 transplants performed yearly. But there are at least 18,000 patients on the transplantation list awaiting cadaveric liver donation. As the waiting list has expanded, waiting time has also grown. As a result, patient mortality has increased while awaiting transplantation and patients are often critically ill by the time of transplantation.
The purpose of the study is to determine if eculizumab is safe and could be used following desensitization therapy to prevent a condition called antibody mediated rejection (AMR).